Effects of Powerlifting-Based Training in Athletes (PLBT-ATH)

February 4, 2026 updated by: Ramazan Erdoğan

The Effects of Powerlifting-Based Training on Hormonal, Metabolic, and Lipid Profile Parameters in Athletes: A Randomized Controlled Trial

This randomized controlled trial aims to examine the effects of a weightlifting-based training program on hormonal, metabolic, and lipid profile parameters in athletes. Participants will be randomly assigned to either a weightlifting-based training group or a control group. The training program will be implemented for a specific period, and relevant blood parameters will be evaluated before and after the intervention. The findings of this study may contribute to a better understanding of the physiological effects of weightlifting-based training on athletes.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

This study is designed as a randomized controlled trial to investigate the effects of a structured weightlifting training program on hormonal, metabolic, and lipid profile parameters in athletes. Eligible participants will be randomly assigned to either an intervention group undergoing a weightlifting-based training protocol or a control group continuing their usual training routines.

The intervention will be implemented over a predetermined training period, and outcome measures will include selected hormonal, metabolic, and lipid profile markers obtained from blood samples. Measurements will be taken at baseline and at the end of the training period. The results of this study are expected to provide evidence on physiological adaptations associated with weightlifting-based training and offer practical implications for training program design in athletic populations.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
30

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Turkey (Türkiye)
    • Center
      • Tunceli, Center, Turkey (Türkiye), 62000
        • Faculty of Sport Sciences
    • Tunceli
      • Bitlis, Tunceli, Turkey (Türkiye), 62000
        • Munzur University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Male basketball players aged 18 to 24 years
  • At least two years of regular sports experience
  • Actively participating in basketball training and competition
  • Voluntary participation with written informed consent

Exclusion Criteria:

  • History of musculoskeletal injury or surgery within the last six months
  • Presence of chronic disease or metabolic disorder
  • Use of performance-enhancing drugs or hormonal supplements
  • Participation in another structured training program during the study period

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Powerlifting-Based Training Group

Participants performed a structured powerlifting-based training program in addition to their regular basketball training. The intervention was conducted three days per week for six weeks. Each session lasted approximately 60 minutes and included a standardized warm-up, a powerlifting-focused main training phase, and a cool-down period.

The training program emphasized the squat, bench press, and deadlift exercises performed with progressive intensity. Accessory exercises targeting lower-body strength, upper-body musculature, and core stability were included. High-intensity bodyweight exercises were also performed to enhance anaerobic capacity and neuromuscular performance. All training sessions were supervised by qualified staff.
Other: Powerlifting-Based Training
Participants will perform a structured powerlifting-based training program including squat, bench press, and deadlift exercises, conducted 3 sessions per week for 8 weeks under supervision.
Other: Blood Sampling and Laboratory Analysis
Venous blood samples were collected from participants at baseline and post-intervention following an overnight fast. Hormonal parameters were analyzed using ELISA methods, and metabolic and lipid profile parameters were analyzed using an automated biochemical analyzer.
Other: Control Group
Participants continued their usual basketball training routines throughout the study period without any additional strength or powerlifting-based exercises.
Other: Blood Sampling and Laboratory Analysis
Venous blood samples were collected from participants at baseline and post-intervention following an overnight fast. Hormonal parameters were analyzed using ELISA methods, and metabolic and lipid profile parameters were analyzed using an automated biochemical analyzer.
Other: Usual Basketball Training
Participants continued their usual basketball training routines without any additional strength or powerlifting-based exercises.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Mean Change in Fasting Serum Total Testosterone Concentration Measured by ELISA (ng/dL)
Time Frame: Baseline and post-intervention (8 weeks)
Mean difference between baseline and post-intervention fasting serum total testosterone concentrations, measured from venous blood samples using a commercially available enzyme-linked immunosorbent assay (ELISA).
Baseline and post-intervention (8 weeks)
Mean Change in Fasting Serum Cortisol Concentration Measured by ELISA (µg/dL)
Time Frame: Baseline and post-intervention (8 weeks)
Mean difference between baseline and post-intervention fasting serum cortisol concentrations, measured from venous blood samples using a commercially available enzyme-linked immunosorbent assay (ELISA).
Baseline and post-intervention (8 weeks)
Mean Change in Fasting Serum Growth Hormone Concentration Measured by ELISA (ng/mL)
Time Frame: Baseline and post-intervention (8 weeks)
Mean difference between baseline and post-intervention fasting serum growth hormone concentrations, measured from venous blood samples using a commercially available enzyme-linked immunosorbent assay (ELISA).
Baseline and post-intervention (8 weeks)
Mean Change in Fasting Serum Thyroid-Stimulating Hormone Concentration Measured by ELISA (µIU/mL)
Time Frame: Baseline and post-intervention (8 weeks)
Mean difference between baseline and post-intervention fasting serum thyroid-stimulating hormone concentrations, measured from venous blood samples using a commercially available enzyme-linked immunosorbent assay (ELISA).
Baseline and post-intervention (8 weeks)
Mean Change in Fasting Serum Triiodothyronine Concentration Measured by ELISA (ng/dL)
Time Frame: Baseline and post-intervention (8 weeks)
Mean difference between baseline and post-intervention fasting serum triiodothyronine concentrations, measured from venous blood samples using a commercially available enzyme-linked immunosorbent assay (ELISA).
Baseline and post-intervention (8 weeks)
Mean Change in Fasting Serum Thyroxine Concentration Measured by ELISA (µg/dL)
Time Frame: Baseline and post-intervention (8 weeks)
Mean difference between baseline and post-intervention fasting serum thyroxine concentrations, measured from venous blood samples using a commercially available enzyme-linked immunosorbent assay (ELISA).
Baseline and post-intervention (8 weeks)

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Mean Change in Fasting Serum Insulin Concentration Measured by ELISA (µIU/mL)
Time Frame: Baseline and post-intervention (8 weeks)
Mean difference between baseline and post-intervention fasting serum insulin concentrations, measured from venous blood samples using a commercially available enzyme-linked immunosorbent assay (ELISA).
Baseline and post-intervention (8 weeks)
Mean Change in Fasting Blood Glucose Concentration Measured by Automated Biochemical Analyzer (mg/dL)
Time Frame: Baseline and post-intervention (8 weeks)
Mean difference between baseline and post-intervention fasting blood glucose concentrations, measured from venous blood samples using an automated biochemical analyzer.
Baseline and post-intervention (8 weeks)
Mean Change in Total Cholesterol Concentration Measured by Automated Biochemical Analyzer (mg/dL)
Time Frame: Baseline and post-intervention (8 weeks)
Mean difference between baseline and post-intervention total cholesterol concentrations, measured from venous blood samples using an automated biochemical analyzer.
Baseline and post-intervention (8 weeks)
Mean Change in Low-Density Lipoprotein Cholesterol Concentration Measured by Automated Biochemical Analyzer (mg/dL)
Time Frame: Baseline and post-intervention (8 weeks)
Mean difference between baseline and post-intervention low-density lipoprotein cholesterol concentrations, measured from venous blood samples using an automated biochemical analyzer.
Baseline and post-intervention (8 weeks)
Mean Change in High-Density Lipoprotein Cholesterol Concentration Measured by Automated Biochemical Analyzer (mg/dL)
Time Frame: Baseline and post-intervention (8 weeks)
Mean difference between baseline and post-intervention high-density lipoprotein cholesterol concentrations, measured from venous blood samples using an automated biochemical analyzer.
Baseline and post-intervention (8 weeks)
Mean Change in Triglyceride Concentration Measured by Automated Biochemical Analyzer (mg/dL)
Time Frame: Baseline and post-intervention (8 weeks)
Mean difference between baseline and post-intervention triglyceride concentrations, measured from venous blood samples using an automated biochemical analyzer.
Baseline and post-intervention (8 weeks)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Ramazan Erdoğan

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
January 10, 2025

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
June 15, 2025

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
October 15, 2025

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
December 29, 2025

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
February 4, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
February 9, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
February 9, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
February 4, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
January 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • E-31679287-663.05-523405 (Other Identifier: Ethics Committee of Dicle University)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Individual participant data will not be shared due to ethical restrictions, participant confidentiality concerns, and the absence of participant consent for data sharing beyond the scope of this study.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Physical Fitness

Clinical Trials on Powerlifting-Based Training

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings